I agree @Bevis17 . I still hold enough SE1 to be keenly following progress, but did reduce my holding on the loss of NanoDX. The key now is progress on CGM, as this project and AbioMed are now the only significant revenue drivers for at least the next 12 months. Abiomed on it's own will keep the company in business, while awaiting the next catalyst ... which is pretty much where we have been for a couple of years now. The CGM project can certainly be that catalyst. I think the 7 day cycle application of the sensor is not appreciated by the market ... so one user of the Sanvita Onetouch CGM for 12 months will use 50 of our sensors.
However, I want to see confirmation of progress and commercialisation of the CGM from SE1 before re-investing.
We await the quarterly.
IMO. GLTAH
SE1 Price at posting:
2.3¢ Sentiment: Hold Disclosure: Held
